ALL NEWS

5467 RESULTS

Sort By:

Results of Ladostigil Trial Published

The Phase 2 study missed its primary endpoint. While fewer developed dementia in the treatment group, the effect was not statistically significant. People on drug had less brain atrophy than those on placebo.

ALS Ice Bucket Challenge Returns for a Repeat Performance in 2015

Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is ...

The Mega-Appeal of Nanomedicine

The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD ...

Cortical Hubs to Rich Clubs—Linking Brain Connectivity to Function

If you find it hard to keep up with Facebook, LinkedIn, and other social networks, spare a thought for the brain. With 100 to 500 trillion synaptic connections, the human brain dwarfs all of them. How do those connections work to formulate thought, recall ...

Task Force Focuses on Tracing Brain Amyloid

Online training for use of Amyvid, the first FDA-approved Aβ imaging ligand, is now up and running,even as a task force convened by the Society of Nuclear Medicine and the Alzheimer's Association scrambles to formulate some expert guidelines on how ...

Stress and Alzheimer’s Disease

With the holidays upon us, are your nerves fraying under the combined pressures of work deadlines, shopping, decorating, and entertaining? Now may be a good time to sit back and consider the effects of stress on the brain. Stress per se is not a cause of ...

DIAN: International Network to Chart AD Preclinical Decade

The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three ...

Guidelines Bring Needed Change, Though Not Enough for Some

U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage. ...

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE